0001209191-15-084255.txt : 20151209 0001209191-15-084255.hdr.sgml : 20151209 20151209163106 ACCESSION NUMBER: 0001209191-15-084255 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151207 FILED AS OF DATE: 20151209 DATE AS OF CHANGE: 20151209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Levy Richard S CENTRAL INDEX KEY: 0001454983 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 151278664 MAIL ADDRESS: STREET 1: EXPERIMENTAL STATION STREET 2: ROUTE 141 AND HENRY CLAY RD CITY: WILMINGTON STATE: DE ZIP: 19880 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-12-07 0 0000879169 INCYTE CORP INCY 0001454983 Levy Richard S 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP, Chief Drug Dev Officer Common Stock 2015-12-07 4 M 0 3937 18.32 A 20863 D Common Stock 2015-12-07 4 S 0 3937 106.18 D 16926 D Non-Qualified Stock Option (right to buy) 18.32 2015-12-07 4 M 0 3937 0.00 D 2020-02-08 Common Stock 3937 6813 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Represents weighted average sale price. Actual sale prices ranged from $105.22 - $109.03. Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. /s/ Richard S. Levy 2015-12-09